サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1643929

ニューロサイエンスの世界市場（2025年～2033年）

Global Neuroscience Market - 2025-2033

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.35円
ニューロサイエンスの世界市場（2025年～2033年）
出版日: 2025年01月27日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のニューロサイエンスの市場規模は、2024年に446億米ドルに達し、2033年には735億米ドルに達すると予測され、予測期間2025年～2033年にはCAGR5.7%で成長する見通しです。

ニューロサイエンスは、神経系の構造、機能、開発、遺伝学、生化学、生理学、病理学の研究に焦点を当てた学際的な科学分野です。ニューロサイエンスの主な目的は、脳と脊髄の複雑なシステムを理解し、それらがどのように相互作用して行動、認知、感情、記憶、知覚、その他の生理学的機能を制御しているかを理解することです。ニューロサイエンスは、神経イメージング、電気生理学、分子生物学、遺伝学、計算モデリングなど、様々な技術やツールを駆使して、脳機能の複雑な側面を探求し、脳関連疾患を治療するための新しいアプローチを開発しています。

ニューロサイエンス市場は、技術の進歩、神経疾患の有病率の増加、ニューロサイエンス分野への研究投資の増加により、大きな成長を遂げています。例えば、2025年1月、BrainSight AIはプレシリーズA投資ラウンドで500万米ドルの資金を確保しました。インドへの進出とFDAの認可を目指す意向です。同社は米国市場に参入し、アフリカと東南アジアの可能性を調査する意向です。同社の製品パッケージはVoxelboxとSnowdropで構成され、脳障害の診断と患者ケアの向上を約束します。

市場力学：

促進要因と抑制要因

ニューロサイエンスにおける技術進歩の高まり

ニューロサイエンスにおける技術進歩の高まりは、ニューロサイエンス市場の成長を大きく後押ししており、予測期間中も市場を牽引していくと予想されます。機能的磁気共鳴画像法（fMRI）、陽電子放射断層撮影法（PET）、脳波検査法（EEG）などの神経画像技術が急速に進歩しています。これらの技術は、脳活動のより良い可視化を可能にし、研究者が神経疾患の根本的な原因を理解し、診断精度を向上させるのに役立っています。

例えば2024年8月、Natus Medical Incorporatedは、臨床脳波データを専門医に匹敵する精度で自動的かつ包括的に解釈できる初の人工知能モデル、autoSCOREを発表しました。Holberg EEGがノルウェーで開発したautoSCOREプログラムは、ディープラーニング・モデルを採用し、入念に注釈が付けられた3万件以上の脳波記録からなる世界最大のデータセットでトレーニングを行いました。autoSCOREアプリケーションは、てんかんに苦しむ数百万人の臨床転帰とヘルスケアの価値を高める可能性を秘めています。

さらに、AI主導のソリューションは、成長するニューロサイエンス市場において重要な役割を果たすと期待されています。特に脳画像、疾病診断、個別化治療の分野におけるAIの応用は、ヘルスケアと医薬品開発分野に革命をもたらす可能性が高いです。

例えば、2024年2月、Royal Philipsは、多発性硬化症（MS）、外傷性脳損傷（TBI）、認知症などの脳障害の診断と治療評価のための客観的意思決定支援における重要な進歩であるSmart Quant Neuro 3Dを発表しました。Smart Quant Neuro 3Dは、フィリップスのAI搭載SmartSpeed画像再構成技術、フィリップスの3D SyntAc臨床アプリケーション、シンセティックMRのSyMRI NEURO 3D定量組織評価ソフトウェアを組み合わせたものです。この統合ソリューションは、医療従事者に診断の信頼性を高める強力なツールを提供し、最終的に患者に利益をもたらします。

希少神経疾患の限られた治療選択肢

希少神経疾患の治療選択肢が限られていることが、ニューロサイエンス市場の成長を妨げると予想されます。少数の患者が罹患するこれらの疾患は、研究、医薬品開発、市場開拓におけるさまざまな課題により、有効な治療法がないことが多いです。ハンチントン病、筋萎縮性側索硬化症（ALS）、脳性麻痺のような疾患は、製薬メーカーからの注目度が低いことが多く、新しい治療法の開発が遅れています。研究は行われているものの、脳や神経系が複雑であるため、これらの疾患の治療は依然として困難です。

希少神経疾患では、患者数が少ないため、臨床試験の参加者を募ることが困難です。このため、製薬会社は大規模で統計的に有意な試験の要件を満たすのに苦労し、医薬品開発の進展を妨げています。例えば、レット症候群やフラジャイルX症候群のような希少な神経遺伝性疾患の臨床試験は、参加者の募集に課題を抱えており、潜在的な治療法の開発を遅らせています。

目次

第1章 市場イントロダクションと範囲

  • レポートの目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • スニペット：タイプ別
  • スニペット：コンポーネント別
  • スニペット：技術別
  • スニペット：エンドユーザー別
  • スニペット：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • ニューロサイエンスにおける技術進歩の高まり
    • 抑制要因
      • 希少神経疾患に対する限られた治療選択肢
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 ニューロサイエンス市場：タイプ別

  • 細胞と分子ニューロサイエンス
  • 認知的ニューロサイエンス
  • 臨床ニューロサイエンス
  • 発達的ニューロサイエンス
  • 行動的ニューロサイエンス
  • 計算論的ニューロサイエンス
  • その他

第6章 ニューロサイエンス市場：コンポーネント別

  • 機器
  • 消耗品
  • ソフトウェアとサービス

第7章 ニューロサイエンス市場：技術別

  • 脳画像
  • 神経顕微鏡検査
  • 定位固定手術
  • 神経プロテオーム解析
  • 神経細胞操作
  • その他

第8章 ニューロサイエンス市場：エンドユーザー別

  • 病院
  • 専門クリニック
  • 診断センター
  • 研究・学術機関
  • その他

第9章 ニューロサイエンス市場：地域別の市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • GE HealthCare
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Medtronic plc
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • B. Braun Melsungen AG
  • Stryker Corporation
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Terumo Corporation
  • Bio-Rad Laboratories, Inc.

第12章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証とバリデーション

第13章 付録

目次
Product Code: MD9055

The global neuroscience market reached US$ 44.6 billion in 2024 and is expected to reach US$ 73.5 billion by 2033, growing at a CAGR of 5.7% during the forecast period 2025-2033.

Neuroscience is a multidisciplinary field of science that focuses on the study of the structure, function, development, genetics, biochemistry, physiology, and pathology of the nervous system. The primary aim of neuroscience is to understand the complex systems of the brain and spinal cord and how they interact to control behavior, cognition, emotions, memory, perception, and other physiological functions. Neuroscience relies on a variety of techniques and tools, including neuroimaging, electrophysiology, molecular biology, genetics, and computational modeling to explore these intricate aspects of brain function and to develop new approaches to treat brain-related disorders.

The neuroscience market is experiencing significant growth, driven by advancements in technology, increasing prevalence of neurological disorders, and rising research investments in the field of neuroscience. For instance, in January 2025, BrainSight AI secured $5 million in funding in a pre-series A investment round. With intentions to expand into India and seek FDA clearance. The company intends to reach US markets and investigate potential in Africa and Southeast Asia. Its product package comprises Voxelbox and Snowdrop, which promise to improve brain disorder diagnosis and patient care.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neuroscience

The rising technological advancements in neuroscience are significantly driving the growth of the neuroscience market and are expected to drive the market over the forecast period. Neuroimaging techniques such as functional Magnetic Resonance Imaging (fMRI), Positron Emission Tomography (PET), and Electroencephalography (EEG) are advancing rapidly. These technologies enable better visualization of brain activity, helping researchers understand the underlying causes of neurological disorders and improving diagnostic accuracy.

For instance, in August 2024, Natus Medical Incorporated launched autoSCORE, the first artificial intelligence model capable of automatically and comprehensively interpreting clinical EEG data with accuracy comparable to medical specialists. Holberg EEG developed the autoSCORE program in Norway, employing a deep-learning model and training on the world's largest dataset of over 30,000 carefully annotated EEG recordings. The autoSCORE application has the potential to enhance clinical outcomes and healthcare value for millions of people suffering from epilepsy.

Additionally, AI-driven solutions are expected to play a significant role in the growing neuroscience market. AI applications, especially in the areas of brain imaging, disease diagnosis, and personalized treatments, are likely to revolutionize the healthcare and drug development sectors.

For instance, in February 2024, Royal Philips introduced Smart Quant Neuro 3D, a significant advancement in objective decision support for the diagnosis and therapy assessment of brain disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), and dementia. Smart Quant Neuro 3D combines Philips' AI-powered SmartSpeed image reconstruction technology, the Philips 3D SyntAc clinical application, and Synthetic MR's SyMRI NEURO 3D quantitative tissue assessment software. The integrated solution provides healthcare providers with powerful tools for increased diagnostic confidence, which ultimately benefits patients.

Limited treatment options for rare neurological disorders

The limited treatment options for rare neurological disorders are expected to hamper the growth of the neuroscience market. These disorders, which affect a small number of patients, often lack effective treatments due to various challenges in research, drug development, and market incentives. Conditions like Huntington's disease, Amyotrophic Lateral Sclerosis (ALS) and Cerebral Palsy often receive less attention from drug manufacturers, slowing progress in developing new therapies. Although some research is being conducted, these diseases remain difficult to treat due to the complexity of the brain and nervous system.

With rare neurological disorders, the small number of patients makes it difficult to recruit participants for clinical trials. This hampers the progress of drug development as pharmaceutical companies struggle to meet the requirements for large-scale, statistically significant trials. For instance, trials for rare neurogenetic diseases such as Rett syndrome or Fragile X syndrome face challenges in recruiting participants, slowing down the development of potential therapies.

Segment Analysis

The global neuroscience market is segmented based on type, component, technology, end-user and region.

Technology:

The brain imaging segment is expected to dominate the neuroscience market share

Brain imaging techniques such as MRI (Magnetic Resonance Imaging), CT (Computed Tomography), fMRI (functional MRI), and PET (Positron Emission Tomography) are indispensable in diagnosing neurological disorders, including Alzheimer's, Parkinson's, epilepsy, and brain tumors. These technologies provide non-invasive, high-resolution insights into brain structure and function.

For instance, in November 2024, Hyperfine, Inc., the pioneering health technology company that revolutionized brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system, the Swoop system, announced CE approval of its latest generation of AI-powered Swoop system software under the European Medical Device Regulation (MDR, EU No. 2017/745). This certification is a crucial step toward Hyperfine's broad European rollout of the Swoop Portable MR Imaging system, which enables faster, high-quality MR brain imaging to assist critical diagnostic choices across a variety of healthcare settings.

Emerging technologies like 3D imaging, AI-assisted image analysis, and quantitative imaging biomarkers are enhancing the precision and efficiency of brain imaging. These advancements allow early diagnosis, improved treatment monitoring, and better research outcomes. AI-integrated imaging tools are used to quickly detect and prioritize brain disorders, saving critical time in treatment.

For instance, in December 2024, GE HealthCare introduced Sonic DL for 3D, the latest addition to their easy imaging portfolio, which is intended to expedite MRI scans in a variety of clinical applications. Sonic DL for 3D draws on GE HealthCare's deep learning innovation legacy and the success of AIR Recon DL, which has assisted more than 34 million patients to date. This extension is expected to maintain the same outstanding 12x acceleration while reducing scan times by up to 86%.

Geographical Analysis

North America is expected to hold a significant position in the neuroscience market share

North America especially the United States leads in the adoption and integration of cutting-edge neuroscience technologies, such as neuroimaging, neurostimulation and artificial intelligence (AI) in the diagnosis and treatment of neurological conditions. The U.S. market is characterized by the rapid adoption of new technologies due to significant investments in innovation and a strong patenting ecosystem. Companies like Medtronic and Boston Scientific are pioneering innovations in neurostimulation devices and other neurotherapeutic products in North America. Similarly, AI applications in neuroimaging are gaining traction for faster, more accurate diagnoses.

For instance, in December 2024, Medtronic gained FDA approval for its Percept RC, which is currently accessible in India. According to the firm, this is the smallest and thinnest two channel neurostimulator available for Deep Brain Stimulation (DBS) systems, representing the most recent improvement in the Percept series. The Percept RC is equipped with BrainSense technology, which detects and records brain signals, providing vital insights that allow healthcare practitioners to adjust and personalize therapy to match each patient's changing needs.

Leading companies such as Eli Lilly, Biogen, Neurocrine Biosciences, and Medtronic and other emerging players such as Neurable Inc. and others are based in North America mostly in the United States and are instrumental in the development of groundbreaking treatments and devices for neurological diseases. These companies contribute to both the research and commercialization of new therapies, advanced devices and technologies for neurological disorders.

For instance, in September 2024, Neurable Inc. introduced the MW75 Neuro, smart headphones that include Neurable's brain-computer interface (BCI) technology to enable users to receive deeper insights into their cognitive health, control burnout, and improve everyday performance. These headphones, the first BCI-enabled consumer-grade item of their type, are poised to transform how we engage with daily technology by allowing users to regulate their health and well-being using the power of their minds.

Asia-Pacific is growing at the fastest pace in the neuroscience market

Asia-Pacific especially India, Japan and China is rapidly adopting new technologies in healthcare, including AI-assisted imaging, neurostimulation devices, and advanced diagnostic tools. This has enhanced the region's capabilities in diagnosing and treating neurological disorders more efficiently. Additionally, companies and hospitals in APAC are also developing advanced and affordable neurostimulation devices for neurological conditions.

For instance, in April 2024, JK Physio and Rehab Clinic announced the debut of the groundbreaking Advanced Exoskeletal Neuro Device, which will revolutionize neurorehabilitation in India. This nerve stimulation device allows complete spinal and muscular mobility, resulting in speedier recovery for both totally and partially paralyzed patients.

Additionally, in November 2023, RapidAI, a health tech firm that specializes in image analysis software, said that it has acquired Class III Shonin approval in Japan and has released a hybrid technology platform called Rapid Edge Cloud, as well as a non-contrast CT product for stroke detection. It offers digital platforms that allow hospital care teams and EMS providers to coordinate treatment, analytics software that helps hospitals run more efficiently, and a clinical trial platform that streamlines the clinical trial screening and enrollment process.

Competitive Landscape

The major global players in the neuroscience market include GE HealthCare, Medtronic plc, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, B. Braun Melsungen AG, Stryker Corporation, Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Bio-Rad Laboratories, Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Neuroscience market report delivers a detailed analysis with 70 key tables, more than 71 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Component
  • 2.5. Snippet by Technology
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Neuroscience
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Treatment Options for Rare Neurological Disorders
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics

5. Neuroscience Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Cellular and Molecular Neuroscience *
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Cognitive Neuroscience
  • 5.4. Clinical Neuroscience
  • 5.5. Developmental Neuroscience
  • 5.6. Behavioral Neuroscience
  • 5.7. Computational Neuroscience
  • 5.8. Others

6. Neuroscience Market, By Component

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 6.1.2. Market Attractiveness Index, By Component
  • 6.2. Instruments*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Consumables
  • 6.4. Software & Services

7. Neuroscience Market, By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Brain Imaging*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neuro-Microscopy
  • 7.4. Stereotaxic Surgeries
  • 7.5. Neuro-Proteomic Analysis
  • 7.6. Neuro-Cellular Manipulation
  • 7.7. Others

8. Neuroscience Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Diagnostic Centers
  • 8.5. Research and Academic Institutes
  • 8.6. Others

9. Neuroscience Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. GE HealthCare*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Medtronic plc
  • 11.3. F. Hoffmann-La Roche Ltd.
  • 11.4. Siemens Healthcare Private Limited
  • 11.5. B. Braun Melsungen AG
  • 11.6. Stryker Corporation
  • 11.7. Abbott Laboratories
  • 11.8. Boston Scientific Corporation
  • 11.9. Terumo Corporation
  • 11.10. Bio-Rad Laboratories, Inc.

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us